About Aldagen
Aldagen is a company based in Durham (United States) founded in 2001 was acquired by Nuo Therapeutics in February 2012. Aldagen has raised $61.53 million across 9 funding rounds from investors including Square 1 Bank, Harbert Management and Nuo Therapeutics. The company has 18 employees as of December 31, 2014. Aldagen operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
- Headquarter Durham, United States
- Employees 18 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aldagen, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$61.53 M (USD)
in 9 rounds
-
Latest Funding Round
$585 K (USD), Series C
Jan 13, 2012
-
Investors
Square 1 Bank
& 10 more
-
Employee Count
18
as on Dec 31, 2014
-
Acquired by
Nuo Therapeutics
(Feb 08, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aldagen
Aldagen has successfully raised a total of $61.53M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $585 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aldagen
Aldagen has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Square 1 Bank, Harbert Management and Nuo Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences and tech focused VC firm funding companies in the US
|
Locked | Locked | Locked | |
|
Infrastructure, hedge, private equity, and debt fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Aldagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aldagen
Investment portfolio details for Aldagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aldagen
Detailed financials for Aldagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aldagen Comparisons
Peer comparison for Aldagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aldagen
Aldagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, MyoKardia, Eiger BioPharmaceuticals and Arrakis Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
Detailed competitors of Aldagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aldagen
Complete news archive for Aldagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aldagen
Aldagen was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Aldagen is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Tom Amick is the current CEO of Aldagen.
Aldagen is a funded company, having raised a total of $61.53M across 9 funding rounds to date.
As of Dec 31, 2014, the latest employee count at Aldagen is 18.
Aldagen was founded in 2001 in Durham, United States, focusing on regenerative medicine. Proprietary technology was utilized to isolate mesenchymal stem cells from patient bone marrow for treating vascular conditions. Clinical trials were conducted for candidates addressing critical limb ischemia, ischemic heart failure, and ischemic stroke. The company was acquired by Cytomedix, now Nuo Therapeutics, in February 2012.
Aldagen's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
Aldagen has 11 investors. Key investors include Square 1 Bank, Harbert Management, Nuo Therapeutics, Piedmont Angel Network, and Intersouth Partners.